Key points are not available for this paper at this time.
Lu-PSMA rechallenge is still active, with lower efficacy and higher toxicity.
Gafita et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: